[Edaily Reporter Shin Ha-yeon ] Pharos iBio Co., Ltd.(388870)announced on the 9th that it will participate in “BIO-Europe 2026,” taking place in Cologne, Germany, from the 9th to the 11th, to hold discussions with global pharmaceutical companies regarding technology transfers of new drug candidates and joint R&D.

BIO-Europe is a major European partnering event where global pharmaceutical and biotech companies, as well as investment institutions, seek opportunities for technology acquisition, transfer, and joint development of new drug pipelines.

At this event, Pharos iBio Co., Ltd. plans to present the R&D achievements and current clinical progress of its core pipeline, including “Rasmotinib (PHI-101),” a treatment for acute myeloid leukemia (AML), and “PHI-501,” a treatment for refractory solid tumors. Through this, the company aims to expand collaboration opportunities with global pharmaceutical companies and identify new technology transfer partners.

Rasmotinib is an anticancer drug candidate that targets the FLT3 mutation, which is found in approximately 35% of patients with acute myeloid leukemia (AML). It is being developed to inhibit major resistance mutations, such as F691L, which are considered limitations of existing FLT3-targeted therapies.

A global Phase 1 clinical trial in patients with relapsed or refractory acute myeloid leukemia has been completed. According to the company, the comprehensive complete remission rate (CRc) in the evaluable patient population from the Phase 1b trial was 50.0%, and the objective response rate (ORR) was 66.7%.

Last month, preclinical study results supporting the potential to overcome resistance to existing FLT3-targeted therapies were published in the international journal *Leukemia*. The company explained that in an animal model with the acquired resistance mutation FLT3-ITD-F691L, the drug demonstrated higher anticancer activity and improved survival compared to existing treatments.

Based on these research results and Phase 1 clinical data, Pharos iBio Co., Ltd. is formulating a strategy to advance to a global Phase 2 clinical trial while simultaneously conducting technology transfer discussions with global pharmaceutical companies.

Another key pipeline candidate, PHI-501, is a therapeutic candidate for refractory solid tumors that simultaneously inhibits the BRAF and DDR1/2 proteins, which are involved in cancer cell growth and drug resistance. It is currently being developed for BRAF-, KRAS-, and NRAS-mutated colorectal cancer and melanoma.

PHI-501 was designed to overcome drug resistance and paradoxical activation—limitations often cited in existing BRAF inhibitors. Nonclinical studies confirmed its tumor growth-inhibiting effects in various BRAF and KRAS mutant animal models, and a Phase 1 clinical trial in South Korea is currently underway, having begun dosing the first patient in January of this year.

Both candidate compounds were developed using Pharos iBio Co., Ltd.’s proprietary artificial intelligence (AI) drug discovery platform, “Chemiverse.” The ADMET module, which predicts a drug’s absorption, distribution, metabolism, excretion, and toxicity characteristics, was utilized for Rasmotinib, while the “DeepRECOM” module, which explores new therapeutic indications for candidate compounds, was used for PHI-501.

Chemiverse is a new drug development platform that integrates data, AI, and laboratory work to perform tasks ranging from disease and target analysis to candidate design, optimization, and experimental validation. The company is utilizing this platform to establish a research and development system that spans from drug candidate discovery through preclinical and clinical development.

Kim Kyu-tae, CEO of Pharos iBio Co., Ltd. and Head of Business Development, stated, “Based on data obtained from the global Phase 1 clinical trial for Rasmotinib, we are actively pursuing technology transfer discussions, and PHI-501 is also increasing its value as a future technology transfer asset as clinical development progresses.” He added, “Through this year’s BioEurope, we will focus on expanding our network with global pharmaceutical companies and translating the technological competitiveness of our key pipelines into tangible technology transfer achievements.”